Key result
Notopterol pretreatment completely prevented the development of heart failure at 28 days post-myocardial infarction in mice by inhibiting adverse cardiac remodeling.
Why the study?
Heart failure frequently results from myocardial infarction, but the role of notopterol and its molecular target in heart failure remain unknown.
Does Notopterol improve cardiac function and attenuate remodeling in a mouse model of post-myocardial infarction heart failure?
Does Notopterol improve cardiac function and attenuate remodeling in a mouse model of post-myocardial infarction heart failure?
Notopterol demonstrates cardioprotective effects in a mouse model of post-MI heart failure by inhibiting cardiac remodeling and hypertrophy via the GSK3β pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in mice; clinical trials needed before considering notopterol for post-MI remodeling.
Introduction: Heart failure (HF), which frequently results from myocardial infarction (MI), leads to death and morbidity to a great extent globally, commonly developed from. Notopterol (NOT) is an active monomer extract obtained from Notopterygium incisum Ting ex H.T. Chang (N. incisum), a traditional Chinese medicine, that is extensively used in the clinical practice of cardiovascular disease and provides definite curative effects. NOT has been proven to be the most abundant constituent enriched in patients' serum and N. incisum ethanol extract. However, the role of NOT and its molecular target in HF remain unknown. Methods: In vivo, left anterior descending (LAD) ligation was conducted for MI induction and then for four weeks to induce HF. Mice were treated with NOT intragastrically for four weeks. Early (0.5 h post-MI) and delayed (12 h post-MI) pre-administration post-MI, as well as a therapeutictreatment after HF, were carried out. Echocardiography was used to assess heart function. H&E staining, wheat germ agglutinin (WGA), as well as Masson trichromatic heart stainings, were applied to evaluate cardiac remodeling, myocardial hypertrophy, and fibrosis, as well as the expression of molecules. In vitro, mouse HL1 cells were treated with NOT after Ang II-stimulation. We measured cardiomyocyte hypertrophythrough α-actinin immunofluorescence staining and hypertrophy gene expression. Meanwhile, phosphorylation of GSK3β is measured after NOT treatment. Then, GSK3β inhibitor 1-AKP was utilized for investigating NOT underlying pathway. Results:In vivo, early (0.5 h p-MI) and delayed (12 h p-MI) pretreatment of NOT alleviated cardiac dysfunction after MI and postponed the onset of HF. Intragastrical administration of NOT after HF prevented adverse cardiac remodeling and attenuated hypertrophy and fibrosis against cardiac injury, as well as inflammation. In vitro, NOT presented an anti-hypertrophy property in cultured HL1 cells subjected to AngⅡ-stimulation. NOT served as an inhibitor of GSK3β; it upregulated the inhibitory phosphorylation of GSK3β, and its beneficial action against heart hypertrophy is partially abolished by inhibiting GSK3β. Conclusion: Our studies show that NOT treatment prevented adverse cardiac remodeling, and attenuated hypertrophy and fibrosis, thereby effectively protecting against the development and progressionof HF. GSK3β pathways are involved in the anti-hypertrophy action of NOT.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) studied Heart failure post-myocardial infarction. Notopterol vs. Vehicle (saline) was evaluated on Incidence of heart failure (ejection fraction < 45%) at 28 days (p=<0.05). Notopterol pretreatment completely prevented the development of heart failure at 28 days post-myocardial infarction in mice by inhibiting adverse cardiac remodeling.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: